If GLP-1 is a common mediator of cardio- and neuroprotection induced by RIC, then administration of GLP-1 stable analogues may offer a better therapeutic solution for the treatment of acute myocardial infarction and ischaemic stroke, especially in patients with autonomic dysfunction. The gene discussed is GLP1R; the disease is acute myocardial infarction.